
Pramlintide improves post‐prandial glucose but requires additional injections. This study investigated the pharmacokinetics, pharmacodynamics (PK/PD), efficacy and safety of ADO09, pramlintide/insulin A21G co‐formulation, in T1D. Based on the study findings, in comparison with aspart, ADO09 was well tolerated and effective in T1D across a wide range of dosages, significantly improving the average blood glucose level and body weight during 24 days of ambulatory treatment. Meal test profiles confirmed improvement of glycemic patterns and other responses with ADO09.
Like
Save
Share